Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDIT101 vs Valaciclovir in Recurrent Genital Herpes
NCT04165122Phase 2Completed
- Sponsor
- Heidelberg ImmunoTherapeutics
- Start
- Nov 2019
- Primary completion
- Aug 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HDIT101 in genital herpes (2 arms), sponsored by Heidelberg ImmunoTherapeutics. Primary endpoint: Percentage of days with lesion(s) per treatment group at 180 days. Started Nov 2019; status: completed.
02
Drugs
HDIT101
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT04165122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165122.